Brief: Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses In Patients With Nsclc From Phase 1 Trial Of Bdtx-1535
14/10/2023 17:42
Oct 14 (Reuters) - Black Diamond Therapeutics Inc
BDTX.O :
* BLACK DIAMOND THERAPEUTICS PRESENTS DOSE ESCALATION DATA
DEMONSTRATING DURABLE RESPONSES IN PATIENTS WITH NSCLC FROM
PHASE 1 TRIAL OF BDTX-1535
* INITIAL NSCLC EXPANSION COHORT DATA EXPECTED IN 2024
* INITIAL GBM DOSE ESCALATION DATA EXPECTED LATER THIS YEAR
Source text for Eikon: ID:nGNX11n7qV
Further company coverage: BDTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Black Diamond Therapeutics
See all newsBlack Diamond Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Black Diamond Therapeutics Q2 net loss narrows year over year
Black Diamond Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Black Diamond Therapeutics Q4 net loss narrows, full-year profit turns positive
U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, Roblox